LANREOTIDE ACETATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LANREOTIDE ACETATE (LANREOTIDE ACETATE).
Lanreotide is a synthetic octapeptide analog of somatostatin. It binds predominantly to somatostatin receptor subtypes 2 (SSTR2) and 5 (SSTR5), inhibiting growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion. It also reduces secretion of gastrointestinal hormones such as serotonin and gastrin.
| Metabolism | Lanreotide is primarily metabolized via peptide hydrolysis; not significantly metabolized by cytochrome P450 enzymes. Renal excretion of unchanged drug is a minor pathway. |
| Excretion | Primarily renal (approximately 60-70% of dose excreted unchanged in urine), with biliary/fecal elimination accounting for about 30%. |
| Half-life | Terminal elimination half-life: 23-30 hours following subcutaneous administration; prolonged in patients with hepatic or renal impairment. |
| Protein binding | Approximately 75% bound to serum proteins (primarily albumin). |
| Volume of Distribution | Approximately 0.3-0.5 L/kg, suggesting distribution primarily into extracellular fluid. |
| Bioavailability | Subcutaneous: ~90% (immediate release); intramuscular (long-acting): full release over 28 days after injection. |
| Onset of Action | Subcutaneous: 1-2 hours for suppression of growth hormone; intramuscular (long-acting formulation): 2-3 weeks. |
| Duration of Action | Subcutaneous: Up to 12 hours; intramuscular (long-acting): 28-35 days. |
90 mg subcutaneously every 4 weeks
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Safety and efficacy not established in severe renal impairment (GFR <30 mL/min) or end-stage renal disease. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). For severe hepatic impairment (Child-Pugh C), use with caution and consider dose reduction to 60 mg every 4 weeks. |
| Pediatric use | Not approved for use in pediatric patients (safety and efficacy not established). |
| Geriatric use | No specific dose adjustment recommended; use with dose monitoring for renal function due to age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LANREOTIDE ACETATE (LANREOTIDE ACETATE).
| Breastfeeding | No data on presence in human milk; likely minimal due to high molecular weight. Caution recommended. M/P ratio unknown. |
| Teratogenic Risk | Insufficient human data; animal studies show no teratogenicity at clinical doses. Somatostatin analogs are generally considered low risk. First trimester: limited data, theoretical risk based on inhibition of growth hormone. Second and third trimesters: no known specific risks. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to lanreotide or any component of the formulation"]
| Precautions | ["Cholelithiasis: Gallbladder sludge or stones may occur; monitor periodically.","Bradycardia: May occur; caution in patients with cardiac conduction abnormalities.","Glucose metabolism: May cause hyperglycemia or hypoglycemia; monitor blood glucose.","Hypothyroidism: May suppress thyroid-stimulating hormone; monitor thyroid function.","Renal impairment: In severe renal impairment, dose adjustment may be required."] |
| Food/Dietary | No known food interactions. Avoid grapefruit juice if taking concomitant CYP3A4 substrates (theoretical, based on somatostatin analog class). |
Loading safety data…
| Monitor maternal blood glucose (risk of hypoglycemia/hyperglycemia), gallstones (ultrasound if symptomatic), and fetal growth (ultrasound) due to potential gastrointestinal effects. |
| Fertility Effects | May suppress pituitary-ovarian axis due to somatostatin analog activity, potentially reducing fertility; clinical significance unclear. |
| Clinical Pearls | Lanreotide acetate is a somatostatin analog used for acromegaly and neuroendocrine tumors. Administer deep subcutaneous injection; rotate sites to prevent lipodystrophy. Monitor gallbladder ultrasound due to risk of gallstones. May cause bradycardia; check ECG in patients with cardiac risk. Dose adjustment not required in renal impairment but caution in severe hepatic impairment. |
| Patient Advice | Inject exactly as prescribed; do not miss doses. Store in refrigerator (2-8°C) and protect from light. · Report signs of gallstones (right upper abdominal pain, nausea) or slow heart rate (dizziness, fatigue). · Do not discontinue abruptly; taper if needed under doctor supervision. · May cause injection site reactions (pain, redness); rotate sites and apply cold compress. · Monitor blood glucose regularly; report hyperglycemia or hypoglycemia symptoms. |